12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Gantenerumab: Phase II expanded

MorphoSys said partner Roche expanded the double-blind, placebo-controlled, international Phase II SCarlet RoAD trial of gantenerumab into a pivotal Phase II/III trial and increased enrollment to 770 from 360 patients in the early or prodromal stage of...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >